Phase II Trial of Nanoparticle Albumin-bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell Lung Cancer
Overview
Pulmonary Medicine
Authors
Affiliations
Introduction: Carboplatin/paclitaxel chemotherapy with bevacizumab is an accepted standard treatment for advanced nonsquamous non-small cell lung cancer (NSCLC). The development of nanoparticle albumin-bound paclitaxel (nab-paclitaxel) has circumvented many of the infusion difficulties associated with standard solvent-based paclitaxel (in Cremophor) and offers theoretical advantages in efficacy. This trial evaluated the combination of nab-paclitaxel, carboplatin, and bevacizumab in advanced (stage IIIB/IV) nonsquamous NSCLC.
Methods: Fifty patients with stage IIIB/IV NSCLC were enrolled between October 2005 and April 2006; 48 were treated with nab-paclitaxel 300 mg/m2, carboplatin area under the curve = 6, and bevacizumab 15 mg/kg every 21 days until progression or intolerable toxicity, up to 4 cycles; an additional 2 cycles could be administered to responding patients and the physician's discretion; maintenance bevacizumab was not administered. Patient demographics included: 56% female, median age 67 years (range, 32-83), performance status 0 (52%) or 1 (48%), adenocarcinoma 86%, and stage IV disease 82%. Responding patients received a minimum of 4 cycles. The primary end point was response rate.
Results: Response rate was 31% with a stable disease rate of 54%. No complete responses were observed. Median progression-free survival was 9.8 months (range, <1-22.3), and median survival was 16.8 months. Most frequent grades 3 and 4 treatment-related toxicities were neutropenia (54%) and fatigue (17%).
Conclusions: The combination of nab-paclitaxel, carboplatin, and bevacizumab was well tolerated with moderate neutropenia. Adverse events were manageable. Survival results are encouraging. These results indicate that this combination has promising activity as first-line therapy in patients with nonsquamous NSCLC.
Ichikawa Y, Seki N, Honda T, Sakugawa M, Hosokawa S, Bessho A Transl Cancer Res. 2023; 12(4):873-886.
PMID: 37180670 PMC: 10175006. DOI: 10.21037/tcr-22-2144.
Zhang Y, Wang Z, Shen L, Li J, Huang J, Su W Cancer Commun (Lond). 2022; 43(1):150-153.
PMID: 36331272 PMC: 9859731. DOI: 10.1002/cac2.12379.
Kahlous Y, Palanirajan V, Starlin M, Negi J, Cheah S Turk J Pharm Sci. 2022; 19(4):391-399.
PMID: 36047535 PMC: 9438755. DOI: 10.4274/tjps.galenos.2021.48961.
Chang S, Qin D, Yan R, Zhang M, Sui B, Xu H ACS Omega. 2021; 6(2):1119-1128.
PMID: 33490771 PMC: 7818125. DOI: 10.1021/acsomega.0c03965.
Wu K, Zhu L, Wang J, Pan K, Wang B, Li X J Thorac Dis. 2020; 11(11):4529-4537.
PMID: 31903241 PMC: 6940262. DOI: 10.21037/jtd.2019.10.81.